Favorites - 5 of 13_banner636885836111106591

  Welcome to the p53Lab
The p53 lab is focusing on the development of new therapies, new diagnostics and new discoveries in the p53 pathway. 11 Million people living with cancer have specific mutations in the p53 gene leading to the production of a faulty p53 protein. This is half the cases of human cancer. In those that have an apparently normal p53 gene we believe that there are faults in the p53 pathway. We are using a variety of approaches to translate this extraordinary finding into clinical benefit. We work closely with many other groups both in Singapore and in the rest of the world to acheive this. We are using biochemical, biophysical, cell biological and genetic approaches in our work and offer an outstanding international training environment.

News & Events

Upcoming Conferences (2019)

23 Sept Singapore 6th Antibody Symposium - Antibody Engineering The Next Wave
12 - 13 Dec Singapore Peptides and Proteins Society Singapore (P2S2) Symposium 2019






Current Publications

The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors. Spiegelberg D, Mortensen AC, Lundsten S, Brown CJ, Lane DP, Nestor M. Cancer Res. 2018 Sep; 78: 5084-5093.

Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision Medicine. Hwang LA, Phang BH, Liew OW, Iqbal J, Koh XH, Koh XY, Othman R, Xue Y, Richards AM, Lane DP, Sabapathy K. Cell Rep. 2018 Jan 2;22(1):299-312.

Exploiting the p53 Pathway for Therapy. Cheok CF, Lane DP. Cold Spring Harb Perspect Med. 2017 Mar 1;7(3). Review

Going native: Complete removal of protein purification affinity tags by simple modification of existing tags and proteases. Goh HC, Sobota RM, Ghadessy FJ, Nirantar S.Protein Expr Purif. 2017 Jan;129:18-24.

Anatomy of Mdm2 and Mdm4 in evolution. Tan BX, Liew HP, Chua JS, Ghadessy FJ, Tan YS, Lane DP, Coffill CR. J Mol Cell Biol. 2017 Feb 1; 9: 3-15. Review

The hot-spot p53R172H mutant promotes formation of giant spermatogonia triggered by DNA damage. Xue Y, Raharja A, Sim W, Wong ES, Rahmat SA, Lane DP. Oncogene. 2017 Apr 6; 36: 2002-2013

Long range recognition and selection in IDPs: the interactions of the C-terminus of p53. Kannan S, Lane DP, Verma CS. Sci Rep. 2016; 6: 23750

Avoiding drug resistance through extended drug target interfaces: a case for stapled peptides. Wei SJ, Chee S, Yurlova L, Lane D, Verma C, Brown C, Ghadessy F. Oncotarget 2016 May 31; 7: 32232

The p53-Mdm2 interaction and the E3 ligase activity of Mdm2/ Mdm4 are conserved from lampreys to humans. Coffill CR, Lee AP, Siau JW, Chee SM, Joseph TL, Tan YS, Madhumalar A, Tay BH, Brenner S, Verma CS, Ghadessy FJ, Venkatesh B, Lane DP. Genes Dev. 2016 Feb 1; 30(3): 281-92.

Stapled peptide design: principles and roles of computation. Tan YS, Lane DP, Verma CS. Drug Discov Today. 2016 Oct; 21: 1642-1653